Aptevo Therapeutics Inc.
APVOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Aptevo Therapeutics Inc. focuses on Biotechnology services and products. Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the. With a market capitalization of $2.9M, it sits in micro-cap territory. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Market Cap
$2.9M
Beta
1.68
P/E (TTM)
0.02
P/E (Fwd)
-0.15
EPS (TTM)
$65.74
EPS (Fwd)
$-10.40
ROE
-420.3%
ROA
-111.5%
Cash
$9.8M
Total Debt
$4.2M
Free CF
-$15.6M
52W Change
-94.2%
Annual Financials
Cash vs Debt
Where APVO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, APVO finished 58.01% below its 150-day moving average ($3.81) and 65.96% below its 200-day moving average ($4.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is APVO overbought or oversold?
At the October 20, 2026 close, APVO's RSI(14) was 25.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Aptevo Therapeutics Inc. holds $9.8M in cash against $4.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$15.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -420.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $3.1M (2022) to $0 (2025), a 100% decline worth watching.
Aptevo Therapeutics Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Aptevo Therapeutics Inc. and its sector.